Piper Sandler downgraded Kinnate Biopharma to Neutral from Overweight with a price target of $4, down from $20.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KNTE:
- Kinnate Biopharma trading resumes
- Kinnate Biopharma to reduce workforce by 70%, announces reprioritization plan
- Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
- Kinnate Biopharma trading halted, news pending
- Kinnate Biopharma reports Q2 EPS (68c), consensus (75c)